公卫人

 找回密码
 立即注册

QQ登录

只需一步,快速开始

查看: 2943|回复: 6

[分享] Design and Analysis of Clinical Trials for Predictive Medicine (2015)

[复制链接]
sampson2010 发表于 2015-5-29 12:57:14 | 显示全部楼层 |阅读模式

注册后推荐绑定QQ,之后方才可以使用下方的“用QQ帐号登录”。

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
# @$ }3 D3 i/ a! k8 l
9781466558151.jpg - {1 f- g2 C8 p7 U

" [9 P* Q4 `  T9 xTitle: Design and Analysis of Clinical Trials for Predictive Medicine) ~! v0 G* W6 c8 e; P' T; C
Author(s): Shigeyuki Matsui; Marc Buyse; Richard Simon
; y; j5 U4 `0 }: X8 MSeries: Chapman & Hall/CRC biostatistics series& U* O+ m+ k( T$ w$ U) A$ j
Publisher: CRC Press
% [9 z1 r7 g) C; s* DCity: Hoboken
1 `( M; L) l/ `4 i! ]5 F# V+ d: }Year: 2015       
$ B3 ^* E! [' c6 h* PLanguage: English        ( V: X  y8 t% c1 r/ I+ B5 J
Pages: 394 p.4 d- k7 _* y; I0 _; T
ISBN: 9781466558168, 14665581644 S0 `3 C# g; e0 s$ g5 e! G2 W1 J
Size: 6 MB (6784770 bytes)        : x% C/ c; ?# E% j* j! T
Extension: pdf

; ~: S& M# V1 B2 C3 K0 a6 _
2 ]4 T6 x1 |+ Z! c5 }: W2 j1 H, C6 M
Features
! M7 T8 K6 I5 T- B$ M8 i. Y
" {' T6 `. x7 T
  • Provides statistical guidance for all stages of clinical trials for predictive medicine
  • Covers all of the main phases in clinical trials for developing molecular diagnostics and therapeutics
  • Presents the state of the art in biostatistics with suggestions for future research topics
  • Includes contributions from key researchers in clinical science and medicine! h- e/ `: u" T# V7 j0 o

! r, [% L9 i8 Q$ Z$ V
8 y7 T9 t$ T$ W) X" h
" C; |, Y: M" l/ R7 k8 b; vSummary/ @7 W8 N1 R' i/ s9 D& K

4 A; c5 d. X/ u$ \5 {4 qDesign and Analysis of Clinical Trials for Predictive Medicine provides statistical guidance on conducting clinical trials for predictive medicine. It covers statistical topics relevant to the main clinical research phases for developing molecular diagnostics and therapeutics—from identifying molecular biomarkers using DNA microarrays to confirming their clinical utility in randomized clinical trials.
8 Z4 s# m% [4 L9 W
3 ?8 A: J# I; EThe foundation of modern clinical trials was laid many years before modern developments in biotechnology and genomics. Drug development in many diseases is now shifting to molecularly targeted treatment. Confronted with such a major break in the evolution toward personalized or predictive medicine, the methodologies for design and analysis of clinical trials is now evolving.
3 i8 b( f& M% v8 I9 M- g2 O% }
0 B% e/ C  ~& kThis book is one of the first attempts to contribute to this evolution by laying a foundation for the use of appropriate statistical designs and methods in future clinical trials for predictive medicine. It is a useful resource for clinical biostatisticians, researchers focusing on predictive medicine, clinical investigators, translational scientists, and graduate biostatistics students.0 i+ G& t+ n( ^4 C6 T" e* ^

2 x: y* [9 i: }/ u9 q# j3 ]' k4 D2 G% G) D1 Q% F. O5 g
Table of Contents
8 B7 u& m6 E, k" O. t. D: L  _0 E8 ^3 I3 R- O  q3 j- s$ X
INTRODUCTORY OVERVIEW& z& `# T/ ~% n% h+ k
Clinical Trials for Predictive Medicine: New Paradigms and Challenges) p" u9 R* b0 A2 P# o
Richard Simon, Shigeyuki Matsui, and Marc Buyse
. j) {7 B7 N# U& h
0 s2 [( R+ u" N- U" Z$ \An Industry Statistician’s Perspective on Personalized Health Care Drug Development( p+ f1 B& S0 H$ [' t
Jane Fridlyand, Ru-Fang Yeh, Howard Mackey, Thomas Bengtsson, Paul Delmar, Greg Spaniolo, and Grazyna Lieberman
( x% i/ G9 M4 Z
$ B5 j  i: {# o3 iAnalytical Validation of In Vitro Diagnostic Tests/ }- h( g+ F) R: r
Robert Becker, Jr." I2 |5 ~9 M! ^) X# m- @# ^
+ e8 ?5 x( b8 Z% h, I- M
EARLY CLINICAL TRIALS USING BIOMARKERS
3 A) V! C4 T; e3 x5 m* vPhase I Dose-Finding Designs and Their Applicability to Targeted Therapies+ j- |" p% ^: n1 ?/ M1 S
Takashi Daimon, Akihiro Hirakawa, and Shigeyuki Matsui- \0 @# s% [+ R+ I0 [1 D

$ Q' j$ r4 `. z! {An Overview of Phase II Clinical Trial Designs with Biomarkers5 [$ x, G5 {( B& J; h- J
Lisa McShane and Sally Hunsberger
4 T: Z- Z+ B4 H& i; ^& o" Q- U3 |/ j6 E  H
Bayesian Adaptive Methods for Clinical Trials of Targeted Agents7 M0 O1 I, r: o: l
Peter Thall  e) Q8 h( J. U' w3 u2 @
$ b/ L, p) k$ @3 E# e# v
Outcome-Adaptive Randomization in Early Clinical Trials4 X9 _8 p1 c( b/ c
Edward Korn and Boris Freidlin
6 d# o% M: \  u" O% ]5 D
: E, F5 @9 o1 d  q0 E$ TChallenges of Using Predictive Biomarkers in Clinical Trials
* Q. L# j$ ~8 wSumithra Mandrekar and Daniel Sargent/ B; D8 ^  X! N# ]  Q( Q- {0 ^% Z

8 S1 j/ j  z- U2 OPHASE III RANDOMIZED CLINICAL TRIALS USING BIOMARKERS! `9 f( {' K7 L. `4 P( L
Comparison of Randomized Clinical Trial Designs for Targeted Agents' f- \1 r/ B; J, {' p
Antje Hoering, Mike LeBlanc, and John Crowley7 Q; r7 ?1 G2 y, e$ K6 a

9 _0 R+ Q  N( N7 d5 N' iPhase III All-Comers Clinical Trials with a Predictive Biomarker
# z  [1 y5 H) t( @, h. n' C* wShigeyuki Matsui, Yuki Choai, and Takahiro Nonaka
0 j' ~4 O+ }5 U( G8 j0 l+ X$ k& ^, }# o4 ^
Evaluation of Clinical Utility and Validation of Gene Signatures in Clinical Trials" i! `# J& S% ?
Stefan Michiels and Federico Rotolo( _/ P/ F* K  X/ f2 b' C
: P; W" M/ ^. R1 [" }3 |& b
ANALYSIS OF HIGH-DIMENSIONAL DATA AND GENOMIC SIGNATURE DEVELOPMENTS
3 ~& b; \3 t$ g8 i  v! t! K) dStatistical Issues in Clinical Development and Validation of Genomic Signatures0 J. ^0 O/ V" {
Shigeyuki Matsui
9 L$ s9 I! q/ y2 Y5 g+ ]5 ~8 Z7 x) j: K6 B9 w4 g! |
Univariate Analysis for Gene Screening: Beyond Multiple Testing* ~+ F6 a! x/ n' E/ r
Hisashi Noma and Shigeyuki Matsui$ M( Z8 i9 {4 S: x( Q

) A2 S3 [5 E; o5 w( XStatistical and Machine-Learning Methods for Class Prediction in High Dimension
" z! y! c, Y5 ^7 }. FOsamu Komori and Shinto Eguchi
% N, x1 ]+ E. D5 U. T2 i! y  }" M4 D+ r
Survival Risk Prediction Using High-Dimensional Molecular Data  M2 q" b" E; l" ]$ G& Q
Harald Binder, Thomas Gerds, and Martin Schumacher8 Z8 c' j& Z. S* Z5 \( W8 t9 K
9 E& ^+ m9 [/ \) U7 l
RANDOMIZED TRIALS WITH BIOMARKER DEVELOPMENT AND VALIDATION0 c6 v5 ?3 O( U/ h& f7 `4 I  k
Adaptive Clinical Trial Designs with Biomarker Development and Validation! i* f& m6 u# x% M# g
Boris Freidlin and Richard Simon: a: o" e2 d0 v

6 ?8 b; e( X0 U$ f- F8 A% RDevelopment and Validation of Continuous Genomic Signatures in Randomized Clinical Trials
/ [, V+ E( F/ L0 \) c$ @* uShigeyuki Matsui
" i% y) ]# Q6 r6 i- W6 P1 F. |1 s: ?; S& z9 ~, O
EVALUATION OF SURROGATE BIOMARKERS
9 U6 @4 }4 N7 S+ |: t( H2 l) `  ~" QBiomarker-Based Surrogate Endpoints
2 d0 b1 f" n1 Q( l0 h2 TMarc Buyse, Tomasz Burzykowski, Geert Molenberghs, and Ariel Alonso( M* z, d3 Z" s& c

) w/ t+ c8 l, B& W: f; Q' r3 M1 h  x3 \
Editor(s) Bio
, ~. h7 Q+ M1 U, r4 ?' H2 h
/ N7 h9 p+ G: vShigeyuki Matsui is a professor in the Department of Biostatistics at Nagoya University Graduate School of Medicine in Japan. He is also a visiting professor at the Institute of Statistical Mathematics. Dr. Matsui has served as council and nominating committee member of the International Biometric Society. He is currently council of the Biometric Society of Japan (BSJ) and editor-in-chief of the Japanese Journal of Biometrics. He is the recipient of the 2014 Award from the BSJ. Dr. Matsui is also a frequent reviewer commissioned by government and advisor to pharmaceutical companies in Japan. He holds degrees in engineering from the Tokyo University of Science in Japan.# }: |- \( q. o/ f& G8 h
- _9 e* ]" j" j' _* y+ F/ C
Marc E. Buyse is the founder of the International Drug Development Institute in Louvain-la-Neuve, Belgium and of CluePoints Inc. in Cambridge, Massachusetts. He is also an associate professor of biostatistics at Hasselt University in Belgium. He was president of the International Society for Clinical Biostatistics, president of the Quetelet Society, and fellow of the Society for Clinical Trials. He worked at the European Organization for Research and Treatment of Cancer in Brussels and at the Dana Farber Cancer Institute in Boston. He holds degrees in engineering and statistics from Brussels University, management from the Cranfield School of Management in the UK, and a doctorate in biostatistics from Harvard University.
; `# S+ `: W+ Q1 K6 q* {- H! ~( m/ o1 d
Richard M. Simon is chief of the Biometric Research Branch at the National Cancer Institute in Bethesda, Maryland. He leads a multidisciplinary group of scientists developing and applying methods for the application of genomics to cancer therapeutics. Dr. Simon is the architect of BRB-ArrayTools software used for the analysis of microarray and digital expression, copy number, and methylation data. He is the recipient of the 2013 Karl E. Peace Award for Outstanding Statistical Contributions for the Betterment of Society and is the author or coauthor of more than 450 publications.1 t4 {, h; ]! D" n% j

! D2 D$ [. X' O2 r7 |! v! {
5 H: ]2 ?. n: D, p; }  I  x Design and Analysis of Clinical Trials for Predictive Medicine (2015).pdf (6.47 MB, 下载次数: 64, 售价: 10 分钢镚)

本帖被以下淘专辑推荐:

jzf1891 发表于 2015-6-23 09:26:07 | 显示全部楼层
下来学习,谢谢无私分享!!!
回复

使用道具 举报

chf521chf521 发表于 2015-8-21 21:24:11 | 显示全部楼层
下载尝试学习学习
回复

使用道具 举报

游青 发表于 2015-8-24 21:23:02 | 显示全部楼层
认真学习一下!
回复

使用道具 举报

Allen刚 发表于 2019-12-26 17:31:46 | 显示全部楼层
谢谢楼主,
回复

使用道具 举报

森森是只乖乖狗 发表于 2019-12-31 15:41:44 | 显示全部楼层
下载来再认真学一番
回复

使用道具 举报

行云半夜 发表于 2020-1-18 00:52:00 | 显示全部楼层
下载并打算认真学习结果发现自己并没有钢蹦……
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

会员|至尊|接种|公卫人 ( 沪ICP备06060850号-3 )

GMT+8, 2020-7-10 14:25 , Processed in 0.149434 second(s), 18 queries , Gzip On, MemCached On.

Powered by Discuz! X3.4

Copyright © 2001-2020, Tencent Cloud.

快速回复 返回顶部 返回列表